This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Inversine with Celexa, mecamylamine hydrochloride with citalopram hydrobromide
Description: TRIDMAC is a combination comprised of mecamylamine hydrochloride (the active ingredient of Inversine) as an augmentation treatment to citalopram hydrobromide.
Inversine is a ganglionic blocker which prevents stimulation of postsynaptic receptors by acetylcholine. The hypotensive effect of Inversine is thought to be due to the reduction in sympathetic tone, vasodilation, and reduced cardiac output. Inversine is approved for the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. Targacept believes that Inversine is prescribed predominantly for the treatment of neuropsychiatric disorders, including Tourette’s syndrome, autism and bipolar disorder. Inversine has been approved for marketing since the 1950s.
Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) with a chemical structure unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other available antidepressant agents. The mechanism of action is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Targacept acquired marketing rights to Inversine in August 2002 from Layton Bioscience, Inc., which had previously acquired the rights from Merck & Co., Inc. In connection with the acquisition, Targacept assumed Laytons obligations under the agreement pursuant to which Layton acquired the rights from Merck. Pursuant to that agreement, Targacept pays Merck an amount each year based on annual sales of Inversine, subject to a specified annual maximum. The annual payment obligation to Merck expires in 2008.
Targacept and Catalyst
In March 2015, Targacept and Catalyst Biosciences jointly announced that they have entered into a definitive agreement to merge the two companies. The combined entity, to be named Catalyst Biosciences, will harness the catalytic power of engineered human proteases to develop next-generation biopharmaceuticals with improved efficacy and therapeutic index to treat major diseases.
In March 2015, Targacept and Catalyst entered into an...See full deal structure in Biomedtracker
Partners: Merck & Co., Inc.
Additional information available to subscribers only: